Skip to content
Ansun Biopharma Logo Ansun Biopharma Logo
  • ABOUT
    • Who We Are
    • Leadership Team
    • Board of Directors
  • RESEARCH & TECHNOLOGIES
    • Respiratory Disease
    • DAS181 Biology
    • Solid Tumors
  • PIPELINE
  • CLINICAL TRIALS
  • INVESTORS & NEWS
  • CAREERS
  • CONTACT

Ansun BioPharma Announces Breakthrough Designation for its Experimental Drug DAS181

Next

Ansun BioPharma Announces Breakthrough Designation for its Experimental Drug DAS181

By abadmin|2021-08-26T07:18:08+00:00October 10th, 2017|Uncategorized|0 Comments

Share This Story, Choose Your Platform!

FacebookXRedditLinkedInWhatsAppTumblrPinterestVkEmail

About the Author: abadmin

Related Posts

Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection

Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection

Ansun BioPharma secures $85 million in Series A Financing

Ansun BioPharma secures $85 million in Series A Financing

Leave A Comment Cancel reply

10045 Mesa Rim Road
San Diego, CA 92121 U.S.A.

Tel: (858) 452-2631

Page load link
Go to Top